CONFERENCE COVERAGE SERIES
Clinical Trials on Alzheimer's Disease 2016
San Diego, California
08 – 10 December 2016
If the setback of the Expedition 3 study of solanezumab set their mood in the beginning, attendees at the 2016 Clinical Trials on Alzheimer’s Disease conference soon bucked up and voiced renewed determination to tackle this illness. Many took positive secondary outcomes and trends in this Phase 3 trial as a sign that this or more potent anti-amyloid drugs given earlier will make a bigger dent in the disease process. Short of major surprises, the meeting reaffirmed the sense that AD will only be slowed by deploying potent drugs at the right target (probably more than one), with the right dose, and certainly at the right time.
CTAD: Solanezumab Seen to Nudge AD Ever so Slightly
Patients on solanezumab saw small improvements on multiple secondary endpoints.
Tau Inhibitor Fails Again—Subgroup Analysis Irks Clinicians at CTAD
The tau aggregation inhibitor LMTM tanks in second Phase 3 trial for Alzheimer’s. The sponsor now plans to develop the “placebo.”
Much ‘Adu’ About a Little: Phase 1 Data Feeds the Buzz at CTAD
Biogen and Genentech rolled out more data from their Phase 1b trials, renewing hope that amyloid removal will work and shoring up dosing for Phase 3.
Tau PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages
At CTAD, tau PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Emerging Alzheimer’s Therapies Test the Waters at CTAD
A few attempts at Alzheimer’s therapy claim hints of promise in early clinical trials, though several did not include placebo controls.